Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; a collaboration agreement with Sanofi Pasteur; and a clinical collaboration with Gritstone Oncology. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
http://www.priceseries.com/trade/IMDZ-Immune-Design-Corp-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2017061520170705.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments